Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2022-10-06 Capital/Financing Update
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a debt settlement by BioVaxys Technology Corp. It details the agreement to settle $300,000 in debt through issuance of common shares. There is no financial report, audit, or detailed financial statements included. The document is an announcement of a financing-related event (debt settlement) rather than a full financial report or earnings release. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. The content aligns with updates on company fundraising or capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2022-10-06 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that BioVaxys Technology Corp. has executed a binding term sheet for marketing and distribution rights in the US for certain products. It details the agreement terms, product descriptions, company background, and forward-looking statements. There are no financial statements, regulatory filings, or detailed financial performance data included. The content focuses on a business development and partnership announcement rather than financial results or regulatory compliance. Therefore, it does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a Capital/Financing Update (CAP) because it relates to a significant business agreement impacting the company's commercial activities and potential revenue streams.
2022-10-06 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2022-09-30 English
Interim MD&A - English.pdf
Regulatory Filings
2022-09-30 English
News release - English.pdf
Regulatory Filings
2022-09-28 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of the final tranche of a non-brokered private placement by BioVaxys Technology Corp. It details the issuance of units, the amount raised, the use of proceeds, and includes forward-looking statements typical of financing announcements. There are no financial statements, audit information, or detailed management discussion of financial results. The content focuses on fundraising activity and capital structure changes. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is 6287 characters, which is sufficient for a detailed announcement but does not constitute a full financial report.
2022-09-20 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.